HLX87 + Pertuzumab
Sponsors
Shanghai Henlius Biotech
Conditions
HER2 + Breast Cancer
Phase 2
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
RecruitingNCT07294508
Start: 2026-02-27End: 2030-12-30Target: 706Updated: 2026-03-20
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Not yet recruitingNCT07294534
Start: 2026-01-27End: 2030-02-01Target: 817Updated: 2025-12-19